Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-184 in Previously Treated AML and NSCLC
NCT04272203Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 1, open-label trial of ABBV-184 in acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose up to 2 years, Complete Remission or Complete Remission With Partial Hematologic Recovery Rate and 1 more. Started May 2020; status: terminated.
02
Drugs
ABBV-184
03
Conditions
acute myeloid leukemia (AML)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04272203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272203.